Table 1.

Guidelines for HBV-infected pregnant women during pregnancy and postpartum.

Guideline	Year of publication	Pregnant women who should receive antiviral intervention	Start antiviral intervention gestational week	First-choice antiviral drug	Puerpera when should discontinue the antiviral intervention	Postpartum monitoring
European Association for the Study of the Liver (EASL) (7)	2017	HBV DNA >200,000 IU/ml or HBsAg >10,000 IU/ml	24–28 weeks	TDF	Continue for up to 12 weeks after delivery	–
American Association for the Study of Liver Diseases (AASLD) (4)	2018	HBV DNA >200,000 IU/ml	28–32 weeks	TDF	Immediately after delivery to 3 months postpartum	Postpartum 6 months for hepatitis flares and seroconversion
Chinese Society of Infectious Diseases, Chinese Medical Association (6)	2019	HBV DNA >200,000 IU/ml	24–28 weeks	TDF	Immediately after delivery or continue up to 1–3 months postpartum	Up to postpartum 6 months
Asian Pacific Association for the Study of Liver (APASL) (5)	2022	HBV DNA >200,000 IU/ml	24–28 weeks	TDF	Immediately after delivery or continue up to 12 weeks postpartum	At least 24 weeks for hepatitis fare and rebound of HBV DNA